Related Experiment Video
Updated: Nov 28, 2025
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Effective RNA Knockdown Using CRISPR-Cas13a and Molecular Targeting of the EML4-ALK Transcript in H3122 Lung Cancer
Saifullah1, Matomo Sakari1, Takeshi Suzuki2,3
1Area of Bioscience and Biotechnology, School of Materials Science, Japan Advanced Institute of Science and Technology (JAIST), 1-1 Asahidai, Nomi City, Ishikawa 923-1292, Japan.
Abstract:
RNAi technology has significant potential as a future therapeutic and could theoretically be used to knock down disease-specific RNAs. However, due to frequent off-target effects, low efficiency, and limited accessibility of nuclear transcripts, the clinical application of the technology remains challenging. In this study, we first assessed the stability of Cas13a mRNA and guide RNA. Next, we titrated Cas13a and guide RNA vectors to achieve effective knockdown of firefly luciferase (FLuc) RNA, used as a target transcript. The interference specificity of Cas13a on guide RNA design was next explored. Subsequently, we targeted the EML4-ALK v1 transcript in H3122 lung cancer cells. As determined by FLuc assay, Cas13a exhibited activity only toward the orientation of the crRNA-guide RNA complex residing at the 5' of the crRNA. The activity of Cas13a was maximal for guide RNAs 24-30 bp in length, with relatively low mismatch tolerance. After knockdown of the EML4-ALK transcript, cell viability was decreased up to 50%. Cas13a could effectively knock down FLuc luminescence (70-76%), mCherry fluorescence (72%), and EML4-ALK at the protein (>80%) and transcript levels (26%). Thus, Cas13a has strong potential for use in RNA regulation and therapeutics, and could contribute to the development of personalized medicine.
Insights
Cas13a RNA interference effectively targets and reduces disease-related RNA, showing promise for new RNA therapeutics and personalized medicine by overcoming limitations of older RNAi technologies.
Area of Science:
- Molecular Biology
- Biotechnology
- Genetics
Background:
- RNA interference (RNAi) holds therapeutic potential but faces challenges like off-target effects and low efficiency.
- Current RNAi limitations hinder clinical applications for disease-specific RNA knockdown.
Purpose of the Study:
- To assess Cas13a RNA interference efficiency and specificity for therapeutic applications.
- To optimize Cas13a and guide RNA (gRNA) vector design for effective target RNA knockdown.
- To evaluate Cas13a's efficacy in reducing disease-associated transcripts like EML4-ALK in cancer cells.
Main Methods:
- Assessed Cas13a mRNA and gRNA stability.
- Titrated Cas13a and gRNA vectors for firefly luciferase (FLuc) RNA knockdown.
- Investigated Cas13a interference specificity related to gRNA design.
- Targeted EML4-ALK v1 transcript in H3122 lung cancer cells.
Main Results:
- Cas13a activity was dependent on crRNA-gRNA complex orientation and optimal gRNA length (24-30 bp) with low mismatch tolerance.
- Achieved significant knockdown of FLuc RNA (70-76%), mCherry (72%), and EML4-ALK protein (>80%) and transcript (26%).
- Reduced H3122 lung cancer cell viability by up to 50% after EML4-ALK knockdown.
Conclusions:
- Cas13a demonstrates potent RNA knockdown capabilities, overcoming some RNAi limitations.
- Cas13a shows strong potential for RNA regulation and development of novel therapeutics.
- This technology could advance personalized medicine approaches by targeting specific disease-related RNAs.
More Related Videos
09:16Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
10:44In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
Published on: May 5, 2023
